COMP <GO>
MOH vs UNH // EV/EBITDA & P/E VALUATION
Molina Healthcare Inc (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MOH 5
— UNH 9
▲ EV/EBITDA & P/E VALUATION LEADER: MOH
LAST: $198.95 (+0.43%) • MKT CAP: $10.39B
valuation
11.4x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOH VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOH | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 13.10% | 88.57% | -75.47 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.20% | 11.47% | +5.73 | MOH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 11.4x | 16.4x | -5.05 | MOH | /valuation <GO> |
| Free Cash Flow Yield | -6.12% | 6.48% | -12.60 | UNH | /fcf-yield <GO> |
| Operating Margin | 1.70% | 4.82% | -3.12 | UNH | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 3.14% | -2.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | 6.46% | +5.24 | MOH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.34 | 3.12 | +1.22 | MOH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 59.2 | -13.00 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.33 | +0.61 | MOH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 17.1x | +3.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.39B | $368.83B | -$358.45B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOH REV | UNH REV | MOH GROSS % | UNH GROSS % | MOH FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $45.43B | $447.57B | 13.1% | 88.7% | -$636.0M | $16.07B |
| FY 2024 | $40.65B | $400.28B | 15.3% | 88.3% | $544.0M | $20.70B |
| FY 2023 | $34.07B | $371.62B | — | 89.6% | $128.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOH // BETA 0.94
UNH // BETA 0.33